AMAG Shareholders Reject $268M Allos Merger

Law360, New York (October 21, 2011, 2:46 PM EDT) -- AMAG Pharmaceuticals Inc. shareholders on Friday rejected the company's proposed $268 million, all-stock acquisition of lymphoma-drug maker Allos Therapeutics Inc.

AMAG, maker of anemia drug Feraheme, announced the proposed merger in July, saying it would pay Allos stockholders .13 shares of AMAG common stock for each share of Allos common stock they owned. The deal was supposed to save the companies between $55 million and $60 million.

"AMAG's board and management team have had a constructive dialogue with our stockholders over the past three months, and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.